{"transactions":[{"id":700036,"issuer":{"id":27424,"kind":"organization","name":"SkyWater Technology, LLC","symbol":"SKYT"},"owners":[{"id":27513,"kind":"person","name":"LaFrence Andrew D.C.","position":1,"cik":"0001850633","reported_name":"LaFrence Andrew D.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-31T14:40:47.000Z","date":"2026-07-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4304,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Represents restricted stock units relating to shares of SkyWater common stock. Pursuant to the Merger Agreement, prior to the Effective Time, each award of restricted stock units relating to shares of SkyWater common stock held by a non-employee member of SkyWater's board of directors that was outstanding, whether vested or unvested, automatically became fully vested and settled in shares of SkyWater common stock. At the Effective Time, each share of SkyWater common stock automatically converted into the right to receive $15 in cash and 0.4883 shares of common stock of IonQ plus cash in lieu of any fractional shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents restricted stock units relating to shares of SkyWater common stock. Pursuant to the Merger Agreement, prior to the Effective Time, each award of restricted stock units relating to shares of SkyWater common stock held by a non-employee member of SkyWater's board of directors that was outstanding, whether vested or unvested, automatically became fully vested and settled in shares of SkyWater common stock. At the Effective Time, each share of SkyWater common stock automatically converted into the right to receive $15 in cash and 0.4883 shares of common stock of IonQ plus cash in lieu of any fractional shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001850633-26-000004","document":"wk-form4_1785508844.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1850633/000185063326000004/wk-form4_1785508844.xml","form_type":"4"}},{"id":700035,"issuer":{"id":27424,"kind":"organization","name":"SkyWater Technology, LLC","symbol":"SKYT"},"owners":[{"id":27513,"kind":"person","name":"LaFrence Andrew D.C.","position":1,"cik":"0001850633","reported_name":"LaFrence Andrew D.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-31T14:40:47.000Z","date":"2026-07-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11428,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares of common stock of SkyWater Technology, Inc. (\"SkyWater\") disposed of pursuant to the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 25, 2026, by and among SkyWater, IonQ, Inc. (\"IonQ\"), Merger Subsidiary 1 Inc. (\"Merger Subsidiary 1\"), and Iris merger Subsidiary 2 LLC (now known as SkyWater Technology, LLC) (\"Surviving Company\"), including the merger of Iris Merger Subsidiary 1 with and into Surviving Company (the \"Second Merger\"). At the effective time of the First Merger (the \"Effective Time\"), each share of SkyWater common stock outstanding immediately prior to the Effective Time (subject to certain exceptions described in the Merger Agreement) automatically converted into the right to receive $15 in cash and 0.4883 shares of common stock of IonQ plus cash in lieu of any fractional shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock of SkyWater Technology, Inc. (\"SkyWater\") disposed of pursuant to the consummation of the transactions contemplated by the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 25, 2026, by and among SkyWater, IonQ, Inc. (\"IonQ\"), Merger Subsidiary 1 Inc. (\"Merger Subsidiary 1\"), and Iris merger Subsidiary 2 LLC (now known as SkyWater Technology, LLC) (\"Surviving Company\"), including the merger of Iris Merger Subsidiary 1 with and into Surviving Company (the \"Second Merger\"). At the effective time of the First Merger (the \"Effective Time\"), each share of SkyWater common stock outstanding immediately prior to the Effective Time (subject to certain exceptions described in the Merger Agreement) automatically converted into the right to receive $15 in cash and 0.4883 shares of common stock of IonQ plus cash in lieu of any fractional shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001850633-26-000004","document":"wk-form4_1785508844.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850633/000185063326000004/wk-form4_1785508844.xml","form_type":"4"}},{"id":740109,"issuer":{"id":27424,"kind":"organization","name":"SkyWater Technology, LLC","symbol":"SKYT"},"owners":[{"id":27513,"kind":"person","name":"LaFrence Andrew D.C.","position":1,"cik":"0001850633","reported_name":"LaFrence Andrew D.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-12T21:09:24.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":4304,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\"). The RSUs vest on the date immediately preceding the next occurring annual meeting of the Issuer's stockholders, contingent on the reporting person's continued service on such vesting date."}],"balance_after":15732,"source":{"system":"sec-edgar","filing":"0001850633-26-000002","document":"wk-form4_1781298561.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850633/000185063326000002/wk-form4_1781298561.xml","form_type":"4"}},{"id":1135527,"issuer":{"id":27424,"kind":"organization","name":"SkyWater Technology, LLC","symbol":"SKYT"},"owners":[{"id":27513,"kind":"person","name":"LaFrence Andrew D.C.","position":1,"cik":"0001850633","reported_name":"LaFrence Andrew D.C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-23T15:35:34.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":11428,"price":8.75,"value":99995.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\"). The RSUs vest on the date immediately preceding the next occurring annual meeting of the Issuer's stockholders, contingent on the reporting person's continued service on such vesting date."}],"balance_after":11428,"source":{"system":"sec-edgar","filing":"0001850633-25-000009","document":"wk-form4_1748014527.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850633/000185063325000009/wk-form4_1748014527.xml","form_type":"4"}},{"id":1722997,"issuer":{"id":7417,"kind":"organization","name":"NORTECH SYSTEMS INC","symbol":"NSYS"},"owners":[{"id":27513,"kind":"person","name":"LaFrence Andrew D.C.","position":1,"cik":"0001850633","reported_name":"LaFrence Andrew D.C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Options","published_at":"2023-12-05T22:22:28.000Z","date":"2023-12-04","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":9.04,"value":361600.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents 40,000 Options granted on December 4, 2023, vesting in equal installments of 8,000 Options on each of December 4, 2024, December 4, 2025, December 4, 2026, December 4, 2027 and December 4, 2028."}],"balance_after":40000,"derivative":{"exercise_price":9.04,"expiration_date":"2033-12-03","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-23-015887","document":"form4-12052023_101224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/722313/000141588923015887/form4-12052023_101224.xml","form_type":"4"}},{"id":1828293,"issuer":{"id":6517,"kind":"organization","name":"KORU Medical Systems, Inc.","symbol":"KRMD"},"owners":[{"id":27513,"kind":"person","name":"LaFrence Andrew D.C.","position":1,"cik":"0001850633","reported_name":"LaFrence Andrew D.C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Options to Purchase Common Stock","published_at":"2023-07-19T00:52:35.000Z","date":"2023-07-15","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Nonqualified stock options granted as an inducement to employment . Options vest in increments of 75,000 on the first anniversary of the date of grant and each anniversary thereafter until fully vested."}],"balance_after":300000,"derivative":{"exercise_price":2.95,"expiration_date":"2033-07-15","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001161697-23-000419","document":"form_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/704440/000116169723000419/form_4.xml","form_type":"4"}},{"id":2327938,"issuer":{"id":116415,"kind":"organization","name":"Vyant Bio, Inc.","symbol":"VYNT"},"owners":[{"id":27513,"kind":"person","name":"LaFrence Andrew D.C.","position":1,"cik":"0001850633","reported_name":"LaFrence Andrew D.C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2022-03-17T20:15:36.000Z","date":"2022-03-15","kind":"grant","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall become exercisable with respect to twenty five percent (25%) of the shares underlying the option upon the date of grant, with respect to thirty seven and a half percent (37.5)% upon the filing by the Company of an Investigational New Drug Application (\"IND\") with the U.S. Food and Drug Administration (\"FDA\") for a New Chemical Entity (\"NCE\") candidate to treat Rett Syndrome and with respect to the remaining thirty seven and a half percent (37.5)% upon the filing by the Company of an IND with the FDA for an NCE candidate to treat CDKL5 Deficiency Disorders; provided that the participant remains a service provider to the Company through each applicable vesting date."}],"balance_after":110000,"derivative":{"exercise_price":1,"expiration_date":"2032-03-15","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001493152-22-007155","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850633/000149315222007155/ownership.xml","form_type":"4"}},{"id":2457230,"issuer":{"id":116415,"kind":"organization","name":"Vyant Bio, Inc.","symbol":"VYNT"},"owners":[{"id":27513,"kind":"person","name":"LaFrence Andrew D.C.","position":1,"cik":"0001850633","reported_name":"LaFrence Andrew D.C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.0001 par value","published_at":"2021-12-29T21:30:29.000Z","date":"2021-11-23","kind":"purchase","acquired":true,"shares":5000,"price":1.9995,"value":9997.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.9995 to $2.00 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."}],"balance_after":34292,"source":{"system":"sec-edgar","filing":"0001493152-21-032696","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850633/000149315221032696/ownership.xml","form_type":"4/A","original_submission_date":"2021-11-24"}},{"id":2495669,"issuer":{"id":116415,"kind":"organization","name":"Vyant Bio, Inc.","symbol":"VYNT"},"owners":[{"id":27513,"kind":"person","name":"LaFrence Andrew D.C.","position":1,"cik":"0001850633","reported_name":"LaFrence Andrew D.C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.0001 par value","published_at":"2021-11-24T21:05:16.000Z","date":"2021-11-23","kind":"purchase","acquired":true,"shares":5000,"price":1.9995,"value":9997.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.9995 to $2.00 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein."}],"balance_after":34336,"source":{"system":"sec-edgar","filing":"0001493152-21-029829","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850633/000149315221029829/ownership.xml","form_type":"4"}},{"id":2635011,"issuer":{"id":116415,"kind":"organization","name":"Vyant Bio, Inc.","symbol":"VYNT"},"owners":[{"id":27513,"kind":"person","name":"LaFrence Andrew D.C.","position":1,"cik":"0001850633","reported_name":"LaFrence Andrew D.C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.0001 par value","published_at":"2021-07-13T13:00:25.000Z","date":"2021-03-30","kind":"other","acquired":true,"shares":26825,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This amended Form 4 is being filed to correct the number of shares of the Issuer's common stock, $0.0001 par value (the \"Common Stock\") issued pursuant to the merger on March 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This amended Form 4 is being filed to correct the number of shares of the Issuer's common stock, $0.0001 par value (the \"Common Stock\") issued pursuant to the merger on March 30, 2021."}],"balance_after":26825,"source":{"system":"sec-edgar","filing":"0001493152-21-016687","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1850633/000149315221016687/ownership.xml","form_type":"4/A","original_submission_date":"2021-04-01"}},{"id":2635010,"issuer":{"id":116415,"kind":"organization","name":"Vyant Bio, Inc.","symbol":"VYNT"},"owners":[{"id":27513,"kind":"person","name":"LaFrence Andrew D.C.","position":1,"cik":"0001850633","reported_name":"LaFrence Andrew D.C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.0001 par value","published_at":"2021-07-13T13:00:25.000Z","date":"2021-03-30","kind":"other","acquired":true,"shares":29292,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This amended Form 4 is being filed to correct the number of shares of the Issuer's common stock, $0.0001 par value (the \"Common Stock\") issued pursuant to the merger on March 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This amended Form 4 is being filed to correct the number of shares of the Issuer's common stock, $0.0001 par value (the \"Common Stock\") issued pursuant to the merger on March 30, 2021."}],"balance_after":29292,"source":{"system":"sec-edgar","filing":"0001493152-21-016687","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850633/000149315221016687/ownership.xml","form_type":"4/A","original_submission_date":"2021-04-01"}},{"id":2701096,"issuer":{"id":116415,"kind":"organization","name":"Vyant Bio, Inc.","symbol":"VYNT"},"owners":[{"id":27513,"kind":"person","name":"LaFrence Andrew D.C.","position":1,"cik":"0001850633","reported_name":"LaFrence Andrew D.C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.0001 par value","published_at":"2021-05-21T20:05:24.000Z","date":"2021-05-20","kind":"purchase","acquired":true,"shares":3000,"price":3.279,"value":9837.0,"ownership":{"direct":true},"balance_after":32336,"source":{"system":"sec-edgar","filing":"0001493152-21-012504","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850633/000149315221012504/ownership.xml","form_type":"4"}},{"id":2764631,"issuer":{"id":116415,"kind":"organization","name":"Vyant Bio, Inc.","symbol":"VYNT"},"owners":[{"id":27513,"kind":"person","name":"LaFrence Andrew D.C.","position":1,"cik":"0001850633","reported_name":"LaFrence Andrew D.C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-04-02T01:24:41.000Z","date":"2021-03-30","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option award was made in accordance with the terms of the Issuer's 2021 Equity Incentive Plan. Subject to continued employment, the option vests as to 25% of the shares on March 30, 2022 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on April 30, 2022."}],"balance_after":100000,"derivative":{"exercise_price":4.61,"expiration_date":"2031-03-30","underlying":"Common stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001493152-21-007807","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1850633/000149315221007807/ownership.xml","form_type":"4"}},{"id":2764630,"issuer":{"id":116415,"kind":"organization","name":"Vyant Bio, Inc.","symbol":"VYNT"},"owners":[{"id":27513,"kind":"person","name":"LaFrence Andrew D.C.","position":1,"cik":"0001850633","reported_name":"LaFrence Andrew D.C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-04-02T01:24:41.000Z","date":"2021-03-30","kind":"other","acquired":true,"shares":38868,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, Reporting Person received options to purchase shares of Common Stock of the Issuer in exchange for options to purchase shares of StemoniX common stock, $0.0001 owned prior to the merger. Subject to continued employment, 38,868 options vest upon the achievement of certain milestones."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, Reporting Person received options to purchase shares of Common Stock of the Issuer in exchange for options to purchase shares of StemoniX common stock, $0.0001 owned prior to the merger. Subject to continued employment, 38,868 options vest upon the achievement of certain milestones."}],"balance_after":38868,"derivative":{"exercise_price":1.56,"expiration_date":"2030-05-22","underlying":"Common stock","underlying_shares":38868},"source":{"system":"sec-edgar","filing":"0001493152-21-007807","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1850633/000149315221007807/ownership.xml","form_type":"4"}},{"id":2764629,"issuer":{"id":116415,"kind":"organization","name":"Vyant Bio, Inc.","symbol":"VYNT"},"owners":[{"id":27513,"kind":"person","name":"LaFrence Andrew D.C.","position":1,"cik":"0001850633","reported_name":"LaFrence Andrew D.C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-04-02T01:24:41.000Z","date":"2021-03-30","kind":"other","acquired":true,"shares":172944,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Reporting Person received options to purchase shares of Common Stock of the Issuer in exchange for options to purchase shares of StemoniX common stock, $0.0001 owned prior to the merger. Subject to continued employment, 111,693 options are currently vested and 61,251 options to vest in equal monthly installments commencing April 30, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, Reporting Person received options to purchase shares of Common Stock of the Issuer in exchange for options to purchase shares of StemoniX common stock, $0.0001 owned prior to the merger. Subject to continued employment, 111,693 options are currently vested and 61,251 options to vest in equal monthly installments commencing April 30, 2021."}],"balance_after":172944,"derivative":{"exercise_price":1.56,"expiration_date":"2029-08-30","underlying":"Common stock","underlying_shares":172944},"source":{"system":"sec-edgar","filing":"0001493152-21-007807","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1850633/000149315221007807/ownership.xml","form_type":"4"}},{"id":2764628,"issuer":{"id":116415,"kind":"organization","name":"Vyant Bio, Inc.","symbol":"VYNT"},"owners":[{"id":27513,"kind":"person","name":"LaFrence Andrew D.C.","position":1,"cik":"0001850633","reported_name":"LaFrence Andrew D.C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.0001 par value","published_at":"2021-04-02T01:24:41.000Z","date":"2021-03-30","kind":"other","acquired":true,"shares":26866,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. (\"Issuer\"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer (\"Merger Sub\") and StemoniX, Inc., a Minnesota corporation (\"StemoniX\") (the \"Merger Agreement\"), Reporting Person received shares of the Issuer's common stock, $0.0001 par value (the \"Common Stock\") in exchange shares of StemoniX common stock, $0.0001 owned prior to the merger."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. (\"Issuer\"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer (\"Merger Sub\") and StemoniX, Inc., a Minnesota corporation (\"StemoniX\") (the \"Merger Agreement\"), Reporting Person received shares of the Issuer's common stock, $0.0001 par value (the \"Common Stock\") in exchange shares of StemoniX common stock, $0.0001 owned prior to the merger."}],"balance_after":26866,"source":{"system":"sec-edgar","filing":"0001493152-21-007807","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1850633/000149315221007807/ownership.xml","form_type":"4"}},{"id":2764627,"issuer":{"id":116415,"kind":"organization","name":"Vyant Bio, Inc.","symbol":"VYNT"},"owners":[{"id":27513,"kind":"person","name":"LaFrence Andrew D.C.","position":1,"cik":"0001850633","reported_name":"LaFrence Andrew D.C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, $0.0001 par value","published_at":"2021-04-02T01:24:41.000Z","date":"2021-03-30","kind":"other","acquired":true,"shares":29336,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. (\"Issuer\"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer (\"Merger Sub\") and StemoniX, Inc., a Minnesota corporation (\"StemoniX\") (the \"Merger Agreement\"), Reporting Person received shares of the Issuer's common stock, $0.0001 par value (the \"Common Stock\") in exchange shares of StemoniX common stock, $0.0001 owned prior to the merger."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. (\"Issuer\"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer (\"Merger Sub\") and StemoniX, Inc., a Minnesota corporation (\"StemoniX\") (the \"Merger Agreement\"), Reporting Person received shares of the Issuer's common stock, $0.0001 par value (the \"Common Stock\") in exchange shares of StemoniX common stock, $0.0001 owned prior to the merger."}],"balance_after":29336,"source":{"system":"sec-edgar","filing":"0001493152-21-007807","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850633/000149315221007807/ownership.xml","form_type":"4"}}]}